Back to Directory Ting-Li Lin Email tlin@sdac.harvard.edu Institution Statistical and Data Analysis Center Title Senior Statistician Request an Update Affiliated Studies IMPAACT 2051: Phase II Study of the Pharmacokinetics, Safety, Tolerability, and Anti-Mycobacterial Activity of Pretomanid with Bedaquiline, Linezolid, with or without Moxifloxacin (BPaL/M) in Children with Rifampicin-Resistant Tuberculosis DAIDS Number 39258 Research Area Tuberculosis Study Status In Development IMPAACT 2034: Phase 1 Study of the Pharmacokinetics, Safety, and Acceptability of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children with Rifampicin-Resistant Tuberculosis DAIDS Number 38754 Research Area Tuberculosis Study Status Enrolling IMPAACT 2020: Phase II Study of Shortened Oral Treatment for Rifampicin-Resistant Tuberculosis in Children DAIDS Number 38505 Research Area Tuberculosis Study Status Withdrawn
IMPAACT 2051: Phase II Study of the Pharmacokinetics, Safety, Tolerability, and Anti-Mycobacterial Activity of Pretomanid with Bedaquiline, Linezolid, with or without Moxifloxacin (BPaL/M) in Children with Rifampicin-Resistant Tuberculosis DAIDS Number 39258 Research Area Tuberculosis Study Status In Development
IMPAACT 2034: Phase 1 Study of the Pharmacokinetics, Safety, and Acceptability of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children with Rifampicin-Resistant Tuberculosis DAIDS Number 38754 Research Area Tuberculosis Study Status Enrolling
IMPAACT 2020: Phase II Study of Shortened Oral Treatment for Rifampicin-Resistant Tuberculosis in Children DAIDS Number 38505 Research Area Tuberculosis Study Status Withdrawn
